Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks.
Demirkaya S et al.
Headache. 2001;41:171-7. All patients with moderate or severe migraine attacks administered 1 g intravenous magnesium sulfate over 15 minutes responded to treatment. The pain-free rate was 87%, pain was diminished in 13%, and accompanying symptoms disappeared in 100%. Treatment was well tolerated.
Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study.
Bigal ME et al.
Cephalalgia. 2002;22:345-53. Intravenous magnesium sulphate (1 g) resulted in a significant lower intensity of photophobia and phonophobia in patients who received magnesium sulphate compared with those treated with placebo (physiological saline) in patients with migraine without aura; the same treatment protocol produced a statistically significant improvement over placebo for pain and all associated symptoms in patients with migraine with aura.
Intravenous magnesium sulfate rapidly alleviates headaches of various types.
Mauskop A et al.
Headache. 1996;36:154-60. This study included 40 patients presenting with a moderate or severe headache of any type; 16 patients had migraines without aura, 9 patients had cluster headaches, 4 patients had chronic tension-type headaches, and 11 had chronic migrainous headaches. Within 15 minutes of intravenous infusion of 1 g of magnesium sulfate, pain was completely eliminated in 80% of the patients. Responses correlated with basal serum ionised magnesium (IMg2+) levels; immediate pain relief was observed in 32 patients and persisted for ≥24 hours in 18 patients, 16 of whom had low serum IMg2+ levels. The lowest initial basal levels of IMg2+ were found in those patients reporting no return of headache or associated symptoms within 24 hours of magnesium infusion. Non-responders exhibited significantly elevated total magnesium levels compared to responders.
No comments:
Post a Comment